Squarepoint’s Vor Biopharma VOR Stock Holding History

Squarepoint’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455K	Buy	25,482 +7,023	+38%	+$99K	﹤0.01%	3390
2025 Q4	$241K	Buy	18,459 +13,730	+290%	+$256K	﹤0.01%	3761
2025 Q3	$230K	Buy	+4,729	New	+$190K	﹤0.01%	3853
2024 Q3	–	Sell	-2,614	Closed	-$52.3K	–	4748
2024 Q2	$52.3K	Buy	+2,614	New	+$84.6K	﹤0.01%	3895
2023 Q4	–	Sell	-785	Closed	-$33.3K	–	4549
2023 Q3	$33.3K	Sell	785 -86	-10%	-$4.66K	﹤0.01%	3670
2023 Q2	$53.8K	Buy	+871	New	+$79.5K	﹤0.01%	3435

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's VOR Position: Q1 2026 in Review

Squarepoint increased its Vor Biopharma (VOR) stake by 38% in Q1 2026, buying an estimated $99K and bringing the position to 25,482 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

Squarepoint first reported a position in VOR in Q2 2023 and has held it in 6 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Squarepoint held 25,482 shares of Vor Biopharma worth $455K as of Q1 2026.
Squarepoint bought 7,023 Vor Biopharma shares in Q1 2026, an estimated $99K.
Vor Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3390 holding.
Squarepoint first reported a position in Vor Biopharma in Q2 2023 and has held it in 6 quarters since.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.